Stocks and Investing
Stocks and Investing
Thu, April 28, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, April 27, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Anita Dushyanth Initiated (URGN) at Strong Buy and Held Target at $20 on, Apr 27th, 2022
Anita Dushyanth of Berenberg, Initiated "UroGen Pharma Ltd." (URGN) at Strong Buy and Held Target at $20 on, Apr 27th, 2022.
Anita has made no other calls on URGN in the last 4 months.
There are 2 other peers that have a rating on URGN. Out of the 2 peers that are also analyzing URGN, 1 agrees with Anita's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Paul Choi of "Goldman Sachs" Maintained at Hold with Increased Target to $11 on, Tuesday, March 22nd, 2022
This is the rating of the analyst that currently disagrees with Anita
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $34 on, Tuesday, January 18th, 2022
Contributing Sources